Diabetic Retinopathy - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 180 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Retinopathy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Retinopathy - Pipeline Review, H1 2015', provides an overview of the Diabetic Retinopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Retinopathy Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Retinopathy - Overview 9
Pipeline Products for Diabetic Retinopathy - Comparative Analysis 10
Diabetic Retinopathy - Therapeutics under Development by Companies 11
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Retinopathy - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Diabetic Retinopathy - Products under Development by Companies 18
Diabetic Retinopathy - Products under Investigation by Universities/Institutes 21
Diabetic Retinopathy - Companies Involved in Therapeutics Development 22
Acucela Inc. 22
Aerpio Therapeutics, Inc. 23
Angstrom Pharmaceuticals, Inc. 24
Antisense Therapeutics Limited 25
Aprogen, Inc. 26
BioDiem Ltd 27
Biomar Microbial Technologies 28
Charlesson LLC. 29
Crinetics Pharmaceuticals, Inc. 30
Dimerix Bioscience Pty Ltd 31
EyeGene, Inc. 32
Foresee Pharmaceuticals, LLC 33
GTx, Inc. 34
Icon Bioscience, Inc. 35
IMMD Inc. 36
Islet Sciences, Inc. 37
Kowa Company, Ltd. 38
LegoChem Biosciences, Inc 39
MacuCLEAR, Inc. 40
MingSight Pharmaceuticals 41
Molecular Design International, Inc. 42
OcuCure Therapeutics, Inc. 43
Ohr Pharmaceutical Inc. 44
PanOptica, Inc. 45
Promedior, Inc. 46
R-Tech Ueno, Ltd. 47
Resolvyx Pharmaceuticals, Inc 48
RestorGenex Corporation 49
Sirnaomics, Inc. 50
Stelic Institute & Co. 51
Stemedica Cell Technologies, Inc. 52
Targazyme, Inc. 53
ThromboGenics NV 54
TWi Pharmaceuticals, Inc. 55
Diabetic Retinopathy - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
49-B - Drug Profile 66
A-6 - Drug Profile 68
A-717 - Drug Profile 70
AC-301 - Drug Profile 71
AKB-9778 - Drug Profile 72
ALG-1001 - Drug Profile 74
AP-202 - Drug Profile 76
ATL-1103 - Drug Profile 77
BDM-E - Drug Profile 79
Beta-LGND2 - Drug Profile 81
CLT-01001 - Drug Profile 83
CLT-01007 - Drug Profile 84
CLT-01012 - Drug Profile 85
cyclosporine - Drug Profile 86
Cyndacel-M - Drug Profile 87
DG-3173 - Drug Profile 88
DMX-200 - Drug Profile 90
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 91
DT-23552 - Drug Profile 92
E-1086 - Drug Profile 93
EG-Mirotin - Drug Profile 94
emixustat hydrochloride - Drug Profile 96
FP-008 - Drug Profile 98
IB-09A0133 - Drug Profile 99
IMD-0354 - Drug Profile 100
JP-153 - Drug Profile 101
L-779976 - Drug Profile 102
LCB-030110 - Drug Profile 103
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 104
MC-4001 - Drug Profile 105
Mesenchymal Stem Cells - Drug Profile 106
MS-553 - Drug Profile 108
OC-10X - Drug Profile 109
ocriplasmin (recombinant) - Drug Profile 110
OLX-302 - Drug Profile 113
PAN-90806 - Drug Profile 114
PRM-167 - Drug Profile 115
Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 116
Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile 117
RES-529 - Drug Profile 118
ripasudil - Drug Profile 120
RTU-007 - Drug Profile 121
RTU-1096 - Drug Profile 122
RX-20001 - Drug Profile 123
squalamine lactate - Drug Profile 124
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 126
STNM-1510 - Drug Profile 127
STP-601 - Drug Profile 128
TZ-101 - Drug Profile 129
V-1932 - Drug Profile 131
Diabetic Retinopathy - Recent Pipeline Updates 132
Diabetic Retinopathy - Dormant Projects 159
Diabetic Retinopathy - Discontinued Products 164
Diabetic Retinopathy - Product Development Milestones 165
Featured News & Press Releases 165
Appendix 175
Methodology 175
Coverage 175
Secondary Research 175
Primary Research 175
Expert Panel Validation 175
Contact Us 175
Disclaimer 176

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2015 13
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Diabetic Retinopathy - Pipeline by Acucela Inc., H1 2015 26
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H1 2015 27
Diabetic Retinopathy - Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015 28
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H1 2015 29
Diabetic Retinopathy - Pipeline by Aprogen, Inc., H1 2015 30
Diabetic Retinopathy - Pipeline by BioDiem Ltd, H1 2015 31
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2015 32
Diabetic Retinopathy - Pipeline by Charlesson LLC., H1 2015 33
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 34
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 35
Diabetic Retinopathy - Pipeline by EyeGene, Inc., H1 2015 36
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 37
Diabetic Retinopathy - Pipeline by GTx, Inc., H1 2015 38
Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H1 2015 39
Diabetic Retinopathy - Pipeline by IMMD Inc., H1 2015 40
Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H1 2015 41
Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H1 2015 42
Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H1 2015 43
Diabetic Retinopathy - Pipeline by MacuCLEAR, Inc., H1 2015 44
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H1 2015 45
Diabetic Retinopathy - Pipeline by Molecular Design International, Inc., H1 2015 46
Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H1 2015 47
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H1 2015 48
Diabetic Retinopathy - Pipeline by PanOptica, Inc., H1 2015 49
Diabetic Retinopathy - Pipeline by Promedior, Inc., H1 2015 50
Diabetic Retinopathy - Pipeline by R-Tech Ueno, Ltd., H1 2015 51
Diabetic Retinopathy - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 52
Diabetic Retinopathy - Pipeline by RestorGenex Corporation, H1 2015 53
Diabetic Retinopathy - Pipeline by Sirnaomics, Inc., H1 2015 54
Diabetic Retinopathy - Pipeline by Stelic Institute & Co., H1 2015 55
Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 56
Diabetic Retinopathy - Pipeline by Targazyme, Inc., H1 2015 57
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2015 58
Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H1 2015 59
Assessment by Monotherapy Products, H1 2015 60
Number of Products by Stage and Target, H1 2015 62
Number of Products by Stage and Mechanism of Action, H1 2015 65
Number of Products by Stage and Route of Administration, H1 2015 67
Number of Products by Stage and Molecule Type, H1 2015 69
Diabetic Retinopathy Therapeutics - Recent Pipeline Updates, H1 2015 136
Diabetic Retinopathy - Dormant Projects, H1 2015 163
Diabetic Retinopathy - Dormant Projects (Contd..1), H1 2015 164
Diabetic Retinopathy - Dormant Projects (Contd..2), H1 2015 165
Diabetic Retinopathy - Dormant Projects (Contd..3), H1 2015 166
Diabetic Retinopathy - Dormant Projects (Contd..4), H1 2015 167
Diabetic Retinopathy - Discontinued Products, H1 2015 168